EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY 4.0

Repurposing of LSD — a scoping review of current clinical trials

Lara Marie Ziegler, Roland Seifert

Naunyn-Schmiedeberg's Archives of Pharmacology · 20.11.2026

DOI: 10.1007/s00210-026-06103-0 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 20.11.2026. Verfasst von Lara Marie Ziegler und 1 weiteren Autor:innen. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medizinische Hochschule Hannover (MHH).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

LSD was banned in many countries for a very long time and was purchased by users for recreational use on the black market. Since 2014, there has been steady growth in interest in its potential use in treating pain disorders and neuropsychiatric conditions. Consequently, an increasing number of studies on the repurposing of LSD have been conducted; in some cases, the conditions treated corresponded to those in studies from the 1950s and 1960s, while in others, the scope was expanded to include new areas of application. Clinicaltrials.org, ANZCTR, the Netherlands trial registry and PubMed research were used to identify the clinical trials. For this publication, 51 studies were analyzed, 25 of which were published. The goal is to map the status quo of the current state of research and analyze the study design. The analysis parameters included study design, conditions, sponsoring, study location, and overall outcome. Most studies are still in phase 1, followed by phase 2. Three phase 3 studies are currently being conducted. The condition entities were: alcohol use disorder ( n = 1), anxiety disorders ( n = 3), Attention-Deficit/Hyperactivity Disorder (ADHD) ( n = 1), cluster headache (chronic and non-chronic, n = 2); major depressive disorder ( n = 4), premenstrual disorders (premenstrual syndrome (PMS)) and Premenstrual Dysphoric Disorder (PMDD) ( n = 1), palliative care/end-of-life distress ( n = 2). The most used dosage is 100 µg. Most studies are interventional RCTs using inactive placebos and are conducted in Switzerland, followed by the USA, the Netherlands, and New Zealand/Australia. The outcome of the published trials was analyzed further. So far, LSD shows possible benefits in the treatment of anxiety disorders and major depressive disorders. The effectiveness of microdosing could not be adequately proven, and the results varied greatly, which could be due to differences in dosage and administration. More detailed studies, particularly phase 2 or phase 3 studies, are needed to make more informed statements.

Förderung

  • Medizinische Hochschule Hannover (MHH)

Zitieren

APA

Ziegler, L. M., & Seifert, R. (2026). Repurposing of LSD — a scoping review of current clinical trials. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-06103-0

Vancouver

Ziegler LM, Seifert R. Repurposing of LSD — a scoping review of current clinical trials. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-06103-0

BibTeX
@article{Ziegler2026,
  author = {Ziegler, Lara Marie and Seifert, Roland},
  title = {Repurposing of LSD — a scoping review of current clinical trials},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  doi = {10.1007/s00210-026-06103-0}
}
Kostenlos starten →